Quality of life and patient-reported outcomes after non-surgical management of early-stage endometrial cancer and endometrial hyperplasia with atypia: a long-term follow-up of the feMMe phase II randomized clinical trial.
Katharina Steger, Eva Baxter, Ruqaiya Al Ramadhani et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase II randomized trial evaluated long-term quality of life and patient-reported outcomes in 44 patients with early-stage endometrial cancer or hyperplasia after non-surgical management using a levonorgestrel intra-uterine device. After a median follow-up of 63 months, the mean quality of life score was 80.5, indicating favorable outcomes across treatment strategies.
Key findings
- The mean quality of life score was 80.5 (SD 16.4) after a median follow-up of 63 months.
- 74.4% of participants reported a positive treatment experience.
- 85.4% would recommend treatment with a levonorgestrel intra-uterine device.
- Self-efficacy for physical activity was significantly better in patients achieving pathologic complete response (p = 0.002).
Why it matters
Understanding long-term quality of life and patient experiences following conservative management of early-stage endometrial cancer is crucial for informing treatment decisions and improving patient care. These outcomes can guide clinicians in discussing options with patients considering non-surgical management.